Biosimilars: Regulatory approval pathway

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

Biosimilars: Regulatory approval pathway

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India


Posters: J Bioanal Biomed

Abstract :

The expiration of patents for a number of blockbuster biologics, increasing pressure for lower cost versions of biological Medicines, ushered in an era of the subsequent production of biosimilar products. A biosimilar medicinal product is a biological medicine which is similar to another biological medicine that has already been authorized for use, the ?reference medicinal product? expected to have the same safety and efficacy profile. The EMA has taken the lead in the regulatory approval framework for biosimilar products, and WHO has published guidelines on the evaluation of biosimilars in order to facilitate the global harmonization. Biosimilarauthorization poses a number of substantial scientific and regulatory challenges for regulatory authorities. Committee for Medicinal Products for Human Use (CHMP) has also issued several product classspecific guidance that sets out product requirements in greater detail. The basic concepts and main principles of approving biosimilars are similar among various nations, notwithstanding some differences in regard to the scope, the choice of reference product, and the data requirement.

Google Scholar citation report
Citations: 3099

Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report

Journal of Bioanalysis & Biomedicine peer review process verified at publons

Indexed In

arrow_upward arrow_upward